ABUS Arbutus Biopharma Corp.

Arbutus to Report First Quarter 2020 Financial Results

Arbutus to Report First Quarter 2020 Financial Results

WARMINSTER, Pa., May 04, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it has scheduled its first quarter financial results, conference call and webcast for Monday, May 11, 2020. The schedule for the press release and conference call/webcast are as follows:

•Q1 2020 Press Release:May 11, 2020 at 6:00 a.m. ET
•Q1 2020 Conference Call/Webcast:May 11, 2020 at 8:00 a.m. ET
•Domestic Dial-In Number:(866) 393-1607
•International Dial-In Number:(914) 495-8556
•Conference ID Number:2993486

A live webcast of the conference call can be accessed through the Investors section of Arbutus' website at or directly at .

An archived webcast will be available on the Arbutus website after the event. Alternatively, you may access a replay of the conference call by calling (855) 859-2056 or (404) 537-3406, and reference conference ID 2993486.

About Arbutus

Arbutus Biopharma Corporation is a publicly-traded (Nasdaq: ABUS) biopharmaceutical company dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic Hepatitis B (HBV) infection. Arbutus is developing multiple drug candidates, each of which have the potential to improve upon the standard of care and contribute to a curative combination regimen. For more information, visit .

Contact Information

Investors and Media

William H. Collier

President and CEO

Phone: 604-419-3200

Email:

Pam Murphy

Investor Relations Consultant

Phone: 604-419-3200

Email:

EN
04/05/2020

Underlying

ABUSArbutus Biopharma Corp.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Arbutus Biopharma Corp.

 PRESS RELEASE
Free
ABUS Arbutus Biophar...

Arbutus Reports Second Quarter 2025 Financial Results and Provides Cor...

Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update Q2 total revenue of $10.7M includes previously-deferred revenue following reacquisition of Greater China rights to imdusiran Dr. Roger Sawhney joins the Arbutus Board of Directors following resignation of Anuj Hasija Dr. Harry Janssen joins the Arbutus Scientific Advisory Board Strong financial position with cash, cash equivalents and marketable securities of $98.1M WARMINSTER, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-s...

August 6, 2025 1 EN
 PRESS RELEASE
Free
ABUS Arbutus Biophar...

Arbutus Reacquires Greater China Rights to Imdusiran and Announces Sci...

Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus Qilu Pharmaceutical and Arbutus mutually agree to conclude strategic partnership for imdusiran in Greater China Drs. Jordan Feld, Ed Gane, Anna Lok, Mark Sulkowski and Man-Fung Yuen join Arbutus Scientific Advisory Board WARMINSTER, Pa., June 25, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced that it has reacquired China ri...

June 25, 2025 1 EN
 PRESS RELEASE
Free
ABUS Arbutus Biophar...

Arbutus Reports First Quarter 2025 Financial Results and Provides Corp...

Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update Imdusiran combination therapy has functionally cured 8 patients with chronic hepatitis B (cHBV) to date, including 2 patients who received no interferon AB-101, oral small-molecule PD-L1 inhibitor, shown generally safe and well-tolerated with evidence of high receptor occupancy in Phase 1a/1b Andrew J. Sung joins Arbutus as General Counsel, bringing more than $28 billion in life sciences deal experience Strong financial position with cash, cash equivalents and marketable securities of $113M WARMINSTER, Pa...

May 14, 2025 1 EN
 PRESS RELEASE
Free
ABUS Arbutus Biophar...

Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusira...

Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025 Data highlighted in late-breaker poster presentation shows that imdusiran achieves functional cure in chronic hepatitis B (cHBV) patients when combined with VTP-300 and low dose nivolumab In a Phase 1a/1b clinical trial, AB-101, an oral PD-L1 inhibitor, has shown to be generally safe and well-tolerated with evidence of high receptor occupancy and no liver dysfunction in cHBV patients WARMINSTER, Pa., May 07, 2025 (GLOBE NEWSWIRE)...

May 7, 2025 1 EN
 PRESS RELEASE
Free
ABUS Arbutus Biophar...

Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025

Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025 Five abstracts accepted for poster presentations WARMINSTER, Pa., April 23, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced that five abstracts, including one late-breaker, have been accepted for presentation at the European Association for the Study of the Liver (EASL) Congress 2025 taking place May 7 - 10, 2025 in Amsterdam, Netherlands. The following abstracts will be presented ...

April 23, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch